These results were the basis for the design of several functional assays to determine whether ACTL6A promotes glioma progression both in vitro and in vivo, and to evaluate YAP/TAZ in glioma cells as a potential mediator of the oncogenic activity of ACTL6A in human cancer. This evidence concerns the gene ACTL6A and glioma.